Basic Information
| LncRNA/CircRNA Name | RP11-134G8.8 |
| Synonyms | RP11-134G8.10 |
| Region | GRCh38_1:201464383-201465146 |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Cisplatin | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | Microarray, qPCR, Flow cytometry assay etc. |
| Sample | cell line (HepG2) |
| Expression Pattern | up-regulated |
| Function Description | After 12, 24 and 48 h of incubation, cisplatin significantly decreased the RP1-193H18.2 level by 2.75, 2.11 and 2.06-fold, respectively. RP11-134G8.8 expression increased by 1.77-2.13-fold, and the RP11-363E7.4 level was also upregulated by 1.89-2.94-fold. These trends in lncRNA expression are consistent with the microarray results. |
| Pubmed ID | 28105167 |
| Year | 2016 |
| Title | Cisplatin induces HepG2 cell cycle arrest through targeting specific long noncoding RNAs and the p53 signaling pathway. |
External Links
| Links for RP11-134G8.8 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |